WXSH0011 / WuXi AppTec - LARVOL DELTA

[VIRTUAL] Preclinical evaluation of WXSH0011, a selective small molecule dual inhibitor of FGFR/c-Met. (ASCO 2020) - "We have identified a novel selective and potent dual FGFR/c-Met inhibitor WXSH0011. Preclinical studies shows antitumor efficacy of WXSH0011 in gastric and liver cancer models. It is currently at IND submission stage."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • FGF • FGFR1 • HGF • MET